Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results.
Biogen reported 52-week Phase 2 AMETHYST data in cutaneous lupus, with 27.2% of patients on litifilimab achieving clear or almost clear skin by Week 52. Placebo crossovers to litifilimab showed rapid benefit.
Biogen said Litifilimab showed rapid and durable efficacy in new 52-week phase 2 data from the ongoing AMETHYST study in cutaneous lupus erythematosus.